This section reviews the side effects, risk factors, adherence challenges, and strategies to mitigate adverse effects associated with these therapies
A few months later the drug gained authorisation in Canada, the European Union, Japan and then Australia in 2019
Product liability lawsuits related to these drugs are typically based on several key claims: The first multi-district litigation (MDL) for GLP-1 RAs was recently established to address the growing number of claims
If you are interested in semaglutide GLP-1 for weight loss, or if you are currently using it and have questions about long-term use, schedule a consultation with our medical team
The primary concern is not established teratogenicity but rather the lack of sufficient safety data during the critical window of egg maturation, embryo development, and early pregnancy
GP participation is voluntary, so coverage varies significantly by integrated care board (ICB, the regional NHS body that decides whats funded locally)
